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ABSTRACT 
New cases of invasive cancer in the United States occur among nearly 1.5 million people annually. In 2007, more 
than 1,500 people died per day with this diagnosis. Cancer is responsible for nearly one in every four deaths reported in 
the country. Enormous amounts of money and research have been, and are being spent, in an attempt to improve these 
numbers. While prevention and early detection remain the key to long-term success, treatment in the neo-adjuvant, 
adjuvant and metastatic settings still centre around two main treatment modalities – radiation therapy and chemotherapy. 
This article will review the advances that have been made in both areas that are making these treatments more precise 
and convenient, as well as less toxic, for the patient. In the field of radiation therapy this involves the development of 
new therapy planning and delivery systems, such as intensity-modulated radiation therapy (IMRT), and positron 
emission and computed tomography, PET-CT. Chemotherapy has also evolved with the development of targeted 
chemotherapy for the treatment of specific malignancies as well as improved supportive care agents which allow for the 
administration of dose-dense chemotherapy when appropriate. © 2008 Biomedical Imaging and Intervention Journal. All 
rights reserved. 
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INTRODUCTION 
The number of new cancer patients diagnosed in the 
United States in 2007 was 1,444,920, excluding patients 
with carcinoma in situ (except of the bladder) and either 
squamous or basal cell carcinoma of the skin. The 
number of deaths attributed to a cancer diagnosis in 2007 
was 559,650, or more than 1,500 people per day. Cancer 
is second only to heart disease as the leading cause of 
death in the country and is responsible for 1 in every 4 
deaths [1]. 
While those statistics are quite grim, the 5-year 
survival rate for all cancers diagnosed was reported to be 
66% in the last years of reporting – 1996 through 2002 – 
which is up substantially from the mid-1970’s when the 
number hovered around 50% [1]. Unfortunately, these 
improvements are not noted in every cancer, nor in every 
patient based upon age, race or sex. There are a number 
of reasons for this dramatic improvement including, but 
not limited to, the advances in detection and treatment of 
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the disease as well as improved supportive care drugs 
and an improved understanding of the molecular changes 
which may contribute to the development of a 
malignancy. These numbers will only improve when the 
data since 2002 becomes available. 
The most common malignancies for women in the 
U.S. as of 2007 are breast cancer (178,480), lung cancer 
(98,620) and colorectal cancer (74,630). The death rates 
associated with these malignancies are 70,880 patients 
with lung cancer, 40,460 patients with breast cancer, and 
26,180 with colorectal cancer. The most common 
malignancies for U.S. males during the same time period 
were prostate cancer (218,890), lung cancer (114,760) 
and colorectal cancer (79,130). Lung cancer was 
responsible for the highest number of deaths at 89,510, 
followed by prostate cancer at 27,050 and colorectal 
cancer at 26,000. [1]. 
The cost of cancer in the U.S. is staggering. For 
2006, the National Institutes of Health estimated the 
overall cost of cancer at USD$206.3 billion. Direct 
medical costs accounted for USD$78.2 billion, indirect 
mortality costs (cost of loss productivity due to illness) 
USD$17.9 billion, and indirect mortality costs (cost of 
lost productivity due to premature death) USD$110.2 
billion [1]. 
The treatment of cancer has revolved around three 
specific treatment modalities – surgery [2], radiation [3,4] 
and chemotherapy [5]. Depending upon the malignancy, 
stage at diagnosis and ultimate treatment goal (cure 
versus palliation) one, two or all three of these treatment 
modalities may be utilised. 
This paper will review the innovations in radiation 
therapy and chemotherapy. 
RADIATION THERAPY BACKGROUND 
Radiation therapy remains one of the most potent 
therapies in the fight against a variety of cancers. In the 
last decade, tremendous advances have heralded 
technological innovations that make treatments more 
precise, convenient and with less toxicity. The 
integration of advanced imaging such as magnetic 
resonance (MRI), positron emission and computed 
tomography (PET-CT) along with other functional 
imaging modalities has augmented the individualisation 
of each patient’s radiation therapy plan. In doing so, each 
patient’s unique plan can be optimised to meet the 
individual goals of treatment.  
In previous decades, radiation teletherapy was 
delivered via rudimentary techniques using radioactive 
sources (e.g. Cobalt-60) mounted in a gantry head. This 
form of radiation therapy is still widely used in many 
parts of the developing world today where access to 
reliable electricity is problematic. The rapid pace of 
development in Asia presents the opportunity for the 
implementation of advanced radiotherapeutic techniques. 
A multidisciplinary approach to cancer care will require 
education, effective screening and prevention, as well as 
monetary and staff investment [6]. 
Radiation Therapy Delivery & Planning Systems 
The development of the linear accelerator at 
Stanford University in the early 1970’s ushered in an era 
of highly complex plans aided by highly sophisticated 
computer controls [7-9]. These complex controls have 
facilitated the implementation of three-dimensional 
conformal radiation therapy (3D-CRT). The goal of 3D-
CRT is to deliver a highly complex combination of 
radiation beam angles and field shapes using CT-based 
dataset to define the target volumes for treatment and 
avoidance of nearby critical structures. Although not 
formally and rigorously tested in any randomised trials 
(versus 2-dimensional radiation therapy), this technique 
has resulted in a significantly improved target definition 
[10,11] and reduction in treatment-related complications 
[12-16]. The introduction of the multi-leaf collimator 
(MLC), a computer-controlled beam shaping device, has 
increased the efficiency of conformal therapy and offered 
several advantages over cerrobend block designs. 
Dynamic shaping of the radiation beam using small, 
mobile tungsten leaves has enabled modulation of the 
radiation beam. Beam modulation can be achieved by 
slowing the movement of the MLC in areas where larger 
doses are to be delivered compared to those areas that 
require protection (e.g. spinal cord). The result of these 
dose distributions in serial adjacent axial slices is the 
desired conformal radiation plan. The composite result of 
this technique is the hallmark of intensity-modulated 
radiation therapy (IMRT). An example of IMRT used to 
treat a cervical cancer with para-aortic disease is 
depicted in Figure 1. 
Clinical outcomes of IMRT have consistently 
demonstrated improvement in clinical endpoints in 
patients with lung cancer, intracranial tumours, prostate, 
gynaecologic and head and neck cancers [17-31]. 
Although the outcomes are quite compelling, clinical 
implementation of IMRT remains a major rate limiting 
step in a variety of practice settings. Although most 
modern linear accelerators are equipped to deliver IMRT, 
very few have delivered these treatments. The main 
barrier to the implementation of these advanced 
programmes is still the lack of clinical training and 
professional development of the clinical staff, i.e. 
radiation oncologist, physicist and/or dosimetrist. The 
labour intensive nature of IMRT planning further 
compounds the implementation of these programmes in 
many small, medium and large centres. Furthermore, 
careful training and implementation of quality assurance 
processes are critical and should be reassessed on a 
routine basis. 
Imaging and Image-guided Radiation Therapy 
The introduction of computed tomography in 
radiation therapy in the early 1980’s was used in the era 
of 3D image-guided radiation therapy. With advances in 
computing power, complex algorithms that better model 
the radiation beam’s interaction with tissues have further 
refined our ability to predict the radiation distribution 
and predict the likely toxicities of treatment. Accurate 
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definition of the target volume has become increasingly 
important as we seek to improve locoregional control 
rates while reducing the toxicities typically seen with 
modern cancer treatments. Multi-modality fusion of 
various imaging modalities such as computed 
tomography (CT), magnetic resonance imaging (MRI), 
positron emission tomography (PET), single-positron 
emission computed tomography (SPECT), amongst 
others, now provides a wealth of functional, biological 
and physiological data. For example, this information 
can now be exploited to target metabolic active or 
hypoxic areas of tumours. The clinical impact of these 
systems has been reported [25, 32, 33] and can be used to 
design complex individualised treatment plans. 
A special application of CT involves time-resolution 
of a moving target such as lung cancer. Compensation of 
physiologic organ motion is critical in highly-conformal 
radiation therapy. Failure to account for target or organ 
motion may result in unacceptable under-dosing of the 
cancer or fatal irradiation of an organ or critical structure. 
However, after accounting for these physiological 
motions, individualised margins can be used to 
significantly reduce complications of treatment by 
reducing the dose delivered to uninvolved tissues while 
offering the opportunity to improve local control rates 
[13-36]. Four-dimensional computed tomography (4D-
CT) now allows clinicians to better assess the tumour or 
organ’s trajectory in near “real-time” so that each 
patient’s radiation plan can be individualised to the 
characteristics of each situation. 
Functional imaging such as magnetic resonance 
spectroscopy (MRS) and positron emission tomography-
computed tomography (PET-CT) has opened new 
frontiers in the characterisation of tumours and their 
unique features. For example, in PET-CT imaging, the 
metabolic function using fluorodeoxyglucose (FDG), 
hypoxia using F-Misonidazole (F-Miso) or proliferation 
using fluoro-thymidine (FLT) can provide valuable 
targets for which targeted systemic agents or 
radiotherapeutic techniques. A summary of PET-CT 
tracers can be found in Table 1. 
Additionally, current linear accelerator technology 
has rapidly evolved to incorporate on-board imaging 
(OBI) which allows for the daily localisation of the 
radiation target volume. These systems in their current 
iterations use either the linear accelerator’s megavoltage 
beam or a separate kilovoltage (kV) source add-on the 
gantry of the linac. This technology generates near 
diagnostic quality images to improve the precision and 
accuracy of patient positioning and treatment verification 
[37-39]. The most significant feature of OBI system is its 
ability to use the kV source to produce volumetric CT 
images immediately prior to each dose of radiation 
treatment. These acquired images can be compared to the 
patient’s initial CT dataset upon which their treatment 
plan was created and adjustments made to the patient’s 
position to ensure the accurate targeting of the radiation 
beam. Only now, with the development of these new 
technologies, has the door been open to near real-time 
adaptive radiation therapy based on target location and 
shape over time. There remains significant work to be 
 
Figure 1  Extended-Field IMRT plan for Cervical Cancer. Note color wash radiation distribution and integrated 
boost treating the pathologically positive pelvic lymph nodes. 
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done to develop guidelines on the specific timing, 
frequency and the degree of adjustment that should be 
made based on the dynamic changes that will 
undoubtedly be seen when image-guided radiation 
therapy is more broadly adopted. Additionally, despite 
these new tools that may allow for more precise targeting 
of disease, operator limitations and multi-modality image 
fusion registration uncertainties are clear limitations and 
pose challenges to the implementation of these advanced 
radiotherapeutic techniques. 
Implications for Modern Therapy in Asia 
The World Cancer Report, the most comprehensive 
global examination of the disease to date, was compiled 
in 2003 by the World Health Organization (WHO) IARC 
[40]. In that report, cancer rates are projected to increase 
by approximately 50% by the year 2020. In Asia, the 
increase is expected to outpace the worldwide average at 
60% to 7.1 million cases per year. The annual incidence 
will climb by 45% to 163 cases per 100,000 people by 
2030, from 112 cases per 100,000 population in 2005. 
Tobacco use, alcohol abuse and the global rise in obesity 
have been identified as the leading cause of the expected 
rise in these rates. This is further complicated by a rising 
life expectancy and an aging population in Asia. 
Previously, the cancer-specific death rate was lower in 
developing countries such as those in Asia, 
predominantly due to infectious diseases. Furthermore, 
the mix of cancer cases appears to be different in Asia 
compared to the Western world. 
Lung cancer, which accounts for the largest number 
of cancer-related deaths, is expected to increase in 
incidence, further outpacing gastric cancer as the second 
most-common cancer with 1.2 million deaths over a 10-
year period from 2005-2015 [WHO IARC report] [40]. 
The increasing Westernisation of the Asian diet is 
expected to drive a similar increase in breast, rectal and 
colon cancer. 
To treat the expected rise in incidence of cancer, 
more sophisticated technologies will need to be brought 
to bear in the fight against the cancer. The vast majority 
of external beam systems in the developing world, 
including most of Asia, use ionising radiation from a 
Cobalt-60 source. Although these systems are quite 
reliable, especially in areas lacking reliable electrical 
power grid, they are unable to deliver the sophisticated 
radiation therapy described above. As the rapid pace of 
development of these countries unfolds and the growth 
rate of cancer incidence is realised, there will be a great 
need to deploy these new methods into clinical practice. 
Challenges for Implementation of Advanced Cancer 
Care in Asia 
Tatsuzki and Levin in 2001 clearly document a 
number of the challenges facing countries in the Far East 
in caring for cancer patients [41]. This survey-based 
report of 17 countries in South Asia, Southeast Asia, East 
Asia and Australia revealed large differences in 
equipment and personnel. For effective use of 
radiotherapy, there must be a planned education 
programme for the general public and for referring 
doctors. Radiotherapy must be a part of a 
multidisciplinary cancer care programme. The 
availability of teletherapy and brachytherapy services 
were clearly based on the economic status of the 
countries examined. In many countries, patients were 
Table 1  PET tracers for metabolic imaging. 
PET radiotracer  Function  Disease 
18F-fluorodeoxyglucose(
18F-FDG)  Glucose metabolism  All tumours 
11C-methionine (
11C-MET)  Amino acid metabolism  Brain/H&N/breast/lung/GU 
11C-tyrosine (
11C-TYR)  Amino acid metabolism  Brain tumours 
15C-oxygen (
15C-O2)  Blood flow  Brain tumours 
18[F]-fluoromisonidazole hypoxia  All  tumours 
15C-carbon monoxide (
15C-O) Blood  volume  Brain  tumours 
Oxygen-15 (
15O2)  Oxygen metabolism  Brain tumours 
11C-5-hydroxy tryptophan (
11C-5-HTP) Serotonin  levels  NE/GI 
15O-water (H2
15O)  Blood flow  Thyroid tumours 
11C-L-dihydroxyphenylalanine (
11C-L-DOPA) Dopamine  levels  NE/pancreatic 
18F-fluoro-2'-deoxyuridine (
18F-FUdR) Nucleic  acid 
metabolism 
Brain tumours 
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treated with CT or fluoroscopy-based systems. Treatment 
planning is also quite basic and often was performed 
without computers. The availability of radiation 
oncologists or cancer specialists further complicates the 
disparity of cancer care often encountered in these 
countries [42]. 
Radiation Summary 
The field of radiation oncology has undergone a 
remarkable transformation in technology and processes 
that have enhanced the therapeutic ratio since the 
discovery of x-rays nearly 100 years ago. As an 
increasing number of countries in the Far East encounter 
the increasing incidence of a variety of cancers, the 
implementation of advanced radiotherapeutic techniques 
will be critical in reducing treatment-related toxicities. 
There is a great need for professional staff training if the 
potential of these advances are to be fully realised. 
CHEMOTHERAPY BACKGROUND 
Chemotherapy has changed a great deal over the 
past several years due to an improved understanding of 
the human genome as well as the molecular nature of 
cancer.  
Treatment even in the early twenty-first century 
centered around the administration of large doses of 
cytotoxic chemotherapy agent(s) that affected any 
actively dividing cell within the body whether it be 
malignant or normal [43]. In some cases, this led to the 
eradication of the cancer but not without significant 
toxicity including life-threatening neutropenia and 
thrombocytopenia, mucositis, alopecia and neuropathy 
[44]. 
Targeted Therapy 
Targeted chemotherapy for the treatment of a 
malignancy was initiated with the US Food and Drug 
Administration (FDA) approval of trastuzumab 
(Herceptin®) in September of 1998. Targeted 
chemotherapy drugs specifically attack the malignant 
cell line, leaving most normal cells unharmed. These 
therapies can be more effective and cause fewer side 
effects than standard cytotoxic chemotherapeutic agents. 
Trastuzumab is a humanised IgG1-kappa monoclonal 
antibody that selectively binds with high affinity to the 
extracellular domain of the human epidermal growth 
factor receptor 2 protein or HER-2 [45]. HER-2 has been 
found to be over-expressed in 20-25% of all women with 
breast cancer. Trastuzumab is a mediator of anti-body-
dependent cellular cytotoxicity (ADCC). This 
trastuzumab-mediated ADCC has been shown to be 
preferentially exerted on HER-2 over-expressing cancer 
cells compared to other cells, including cancer cells that 
do not over-express HER2. The specificity of 
trastuzumab for cells which over-express HER-2 
dramatically decreases the toxicity of the drug to normal 
cells. The common side effects associated with the 
administration of non-specific chemotherapeutic agents 
such as myelosuppression, mucositis and alopecia are not 
associated with the administration of trastuzumab. That 
is not to say that the drug is devoid of all toxicity, 
however. Infusion reactions, including dyspnea, 
hypotension and anaphylaxis have been reported with the 
use of the drug and all monoclonal antibodies, but are 
rare and manageable. Cardiomyopathy as evidenced by 
sub-clinical and clinical congestive heart failure and a 
decrease in left ventricular ejection fraction (LVEF) has 
been noted particularly in patients who receive 
trastuzumab with a concurrently administered 
anthracycline such as doxorubicin, an agent with 
recognised cardiac toxicity [45]. The cardiomyopathy 
associated with patients receiving an anthracycline in 
combination with trastuzumab is a late complication of 
therapy. While the dose-dependent cardiac toxicity of 
anthracyclines is well established [46], it is unclear at 
this point in time whether the same can be said for the 
continued use of single agent trastuzumab. A review of 
the spectrum and reversibility of the cardiotoxicity 
observed in the adjuvant trastuzumab trials was recently 
reported [47]. Up to 4% of patients enrolled onto 
adjuvant trastuzumab trials experienced severe 
congestive heart failure during treatment with a larger 
proportion of patients experiencing a sustained decrease 
in their left ventricular ejection fraction to less than 50%. 
Studies are ongoing to better characterise whether or not 
this is a dose-dependent event.  
Lapatinib [48] is an oral tyrosine kinase inhibitor 
(TKI) which acts at both the epidermal growth factor 
(ErbB1) and the HER2 (ErbB2) receptor sites. It binds 
reversibly to tyrosine kinase blocking phosphorylation 
and activation of downstream secondary messengers 
thereby regulating the proliferation and survival in 
ErbB1 and HER2 expressing tumours. It is currently 
FDA-approved in combination with the oral pyrimidine 
analogue capecitabine for the treatment of patients with 
HER2 over-expressing advanced or metastatic breast 
cancer who have received previous therapy with an 
anthracycline, a taxane and trastuzumab [49]. 
Lapatinib, being a small molecule, has been shown 
to penetrate the blood brain barrier and is now being 
evaluated as a potential treatment in patients with 
metastatic breast cancer with brain involvement [50]. 
Phase I data on the combination of trastuzumab and 
lapatinib has recently been published [51]. Since 
trastuzumab targets the extracellular domain of HER2 
(ErbB2) and lapatinib acts intracellularly with specificity 
for both the ErbB1 and ErbB2 receptors, this 
combination may prove to be of value in patients with 
HER2 (+) breast cancer. Patients were treated with 
escalating doses of lapatinib, 750 to 1500 mg 
administered orally once daily, in combination with 
trastuzumab at the standard dose of a 4 mg/kg IV loading 
dose followed by a 2 mg/kg weekly maintenance dose. 
The primary endpoint of the study was to assess the 
safety, clinical feasibility, optimally tolerated regimen 
(OTR), pharmacokinetics and preliminary activity. The 
OTR of the combination was lapatinib 1000 mg per day 
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with standard weekly trastuzumab. The most frequent 
grade 3 drug related toxicities were diarrhoea, fatigue 
and rash. Of the 54 patients treated, all of whom were 
heavily pretreated, one patient achieved a complete 
response and an additional seven patients had a partial 
response. The authors concluded that the combination of 
trastuzumab and lapatinib at the doses listed above was 
well tolerated and clinically active in this patient 
population. 
O’Shaughnessy et al. conducted the first Phase III 
randomised open-labeled, multi-centered study 
evaluating lapatinib versus lapatinib + trastuzumab in 
heavily pre-treated women with HER2+ metastatic breast 
cancer. Preliminary results were reported at the 2008 
American Society of Clinical Oncology (ASCO) meeting 
in Chicago [52]. Two hundred and ninety six women 
were randomised and the average prior number of 
chemotherapy regimens was 6. Progression-free survival 
(12.0 weeks vs. 8.4 weeks; p=0.029) and clinical benefit 
at 24 weeks (25.2% vs. 13.2%; p=0.020) both favoured 
the combination therapy. There was also a trend towards 
a higher response rate (10.3% vs. 6.9%) and overall 
survival (51.6 weeks vs. 39 weeks) in those patients 
treated with the combination of lapatinib and 
trastuzumab. The full manuscript of this important study 
will be published in the near future. 
An investigational agent that shows great promise in 
the treatment of a number of malignancies is pertuzumab 
[53]. It is a recombinant humanised monoclonal antibody 
which binds to the extracellular domain II of the HER2 
receptor and blocks its ability to dimerise with other 
HER receptors. Dimerisation, or the pairing with other 
receptor proteins, is essential for HER receptor activity 
and may well play a role in the growth and survival of 
cancer cells. This activity is distinctly different from 
other monoclonal antibodies such as trastuzumab or the 
tyrosine kinase inhibitors such as erlotinib. The Phase I 
study of the drug in patients with advanced cancer has 
shown the drug to be well tolerated, have clinical activity 
in a variety of tumour types and a pharmacokinetic 
profile which allows for a 3-week dosing interval. 
Additional studies are ongoing particularly in patients 
with metastatic breast cancer. 
Other malignancies which have been treated very 
effectively with targeted chemotherapy include chronic 
myelogenous leukaemia (CML) and gastrointestinal 
stromal tumours (GIST), both with the oral agent 
imatinib mesylate. 
A list of other FDA approved targeted therapy for 
the treatment of cancer in the US is shown in Table 2. 
Improvements in Supportive Care 
Besides the dramatic increase in the number of new, 
targeted therapies, the majority of which have less 
toxicity than the older cytotoxic agents, supportive care 
has also improved the tolerability of chemotherapy 
administration. The major advances have come in the 
areas of anti-emetics, growth factor support and bone 
health.  
Anti-Emetics 
New classes of anti-emetics, such as the serotonin 
(5-HT3) receptor antagonists and neuro-kinin 1 (NK-1) 
antagonists, have played a major role in decreasing the 
incidence and severity of chemotherapy-induced nausea 
and vomiting (CINV). See Table 3.  
Combination therapy with members from each of 
these classes along with a steroid, usually 
dexamethasone, have become the standard of care for 
patients receiving moderately or highly emetogenic 
chemotherapy. 
Growth Factors 
Growth factor support (see Table 4), particularly 
white cell factors, has allowed for an increase in dose 
intensity which is a primary treatment end point for 
patients with early stage breast cancer and lymphomas 
and may also play a role in other malignancies. The 
advent of long acting factors such as pegfilgrastim have 
allowed for a single dose of the growth factor per cycle 
versus daily subcutaneous administration for 7-10 days 
as was usually seen with filgrastim or sargramostim. The 
red cell growth factors have allowed for a decrease in the 
need for red blood cell transfusions in patients actively 
being treated for their malignancies. Recent studies have 
shown an increase in risk of thrombosis and death if 
these agents are used to increase haemoglobin levels to 
greater than 12 gm/dl in some groups of patients not 
actively being treated with chemotherapy. A long-acting 
formulation, darbepoietin, has allowed for dosing every 2 
to 3 weeks with these agents, which is an advantage over 
the once-a-week schedule most commonly used with 
epoetin alfa. 
Bone Health 
The bisphosphonates, pamidronate and zoledronic 
acid, are extensively used in the oncology population to 
treat or prevent skeletal related events secondary to a 
number of malignancies including breast cancer, multiple 
myeloma and prostate cancer. See Table 5. They are also 
considered to be the drugs of choice for the treatment of 
hypercalcemia related to malignancy. 
New Findings 
Data was recently presented at the 2008 American 
Society of Clinical Oncology (ASCO) meeting in 
Chicago regarding an improved outcome for 
premenopausal women with early breast cancer treated 
with endocrine therapy, tamoxifen or anastrozole with 
goserelin, and zolendronic acid [69]. Adjuvant 
bisphosphonate therapy with zoledronic acid was 
included in two of the four treatment arms to mitigate the 
bone loss associated with complete ovarian suppression 
and to explore the antitumour effects previously 
demonstrated in preclinical trials. Patients were treated 
with oral tamoxifen and goserelin +/- zoledronic acid 
which was compared to oral anastrozole and goserelin 
+/- zoledronic acid for 3 years. At least 900 patients were 
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Table 2  FDA approved targeted therapy for the treatment of cancer in the US 
Extra-Cellular Receptor Blockage 
Drug Mechanism  of  Action  Disease  Toxicity 
Alemtuzumab [54]  Blocks CD52  CLL/Lymphoma  Myelosuppression 
Cetuximab[55]  Blocks EGFR  Colon cancer  Skin rash 
Panitubumab[56]  Blocks EGFR  Colon cancer  Skin rash 
Rituximab [57]  Blocks CD20  Lymphoma  Infusion reactions 
Trastuzumab[58] Blocks  HER2  Breast  Cancer  Cardiac 
Neutralizes Extra-Cellular Growth Factors 
Drug Mechanism  of  Action  Disease  Toxicity 
Bevacizumab [(59]  Binds to VEGF  Colon, Lung, Breast cancer  Skin rash 
Intra-Cellular Tyrosine Kinase Inhibitors 
Drug Mechanism  of  Action  Disease  Toxicity 
Dasatinib [60]  Inhibits bcr-abl TK  CML  Fluid retention 
Gefitinib [61]  Inhibits TK  Lung cancer  Skin rash 
Imatinib [62]  Inhibits bcr-abl TK  CML  Fluid retention 
Intra-Cellular EGFR (HER-1) Inhibitors 
Drug Mechanism  of  Action  Disease  Toxicity 
Erlotinib [63]  Inhibits HER-1  Lung cancer  Skin Rash 
Intra-Cellular Tyrosine Kinase/EGFR Inhibitors 
Drug Mechanism  of  Action  Disease  Toxicity 
Lapatinib [48]  TK/EGFR Inhibitor  Breast cancer  Hand-Foot Syndrome 
Intra-Cellular m-TOR Inhibitors 
Drug Mechanism  of  Action  Disease  Toxicity 
Temsirolimus [64]  m-TOR inhibitor  Renal cancer  Myelosuppression 
Intra-Cellular Multi-Kinase Inhibitors 
Drug Mechanism  of  Action  Disease  Toxicity 
Sunitinib [64]  Multi-TK Inhibitor  Renal cancer  Diarrhoea 
Intra-Cellular and Surface Kinase Inhibitors 
Drug Mechanism  of  Action  Disease  Toxicity 
Sorafenib [64]  Multi-TK Inhibitor  Renal Cancer  Diarrhoea 
Intra-Cellular Proteasome Inhibitors 
Drug Mechanism  of  Action  Disease  Toxicity 
Bortezomib [65]  Proteasome Inhibitor  Myeloma  Neurotoxicity 
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Table 3 New  Anti-Emetic  Drugs 
Serotonin (5-HT3) Receptor Antagonists 
Drug  Route of Administration 
Dolasetron [66]  IV, PO 
Granisetron [66]  IV, PO 
Ondansetron [66]  IV, PO 
Palonosetron [66]  IV, PO 
Neurokinin-1 Antagonists 
Drug  Route of Administration 





Table 4  Growth Factor Support 
White Cell Growth Factors 
Drug  Route of Administration  Frequency 
Filgrastim [67]  SQ  Daily for 7-10 days 
Sargramostim [67]  SQ  Daily for 7-10 days 
Pegfilgrastim [67]  SQ  Once per cycle 
Red Cell Growth Factors 
Drug  Route of Administration  Frequency 
Darbepoietin [68]  SQ  Every 2-3 weeks 





Table 5 Bisphosphonates 
Treatment/Prevention of Skeletal Related Events 
Drug  Route of Administration  Frequency 
Pamidronate [70]  IV  Every 3-4 weeks 
Zoledronic acid [70]  IV  Every 3-4 weeks 
Treatment of Hypercalcemia Secondary to Malignancy 
Drug  Route of Administration  Frequency 
Pamidronate [71]  IV  Every 7 days 
Zoledronic acid [71]  IV  Every 7 days 
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treated with either tamoxifen or anastrozole. The primary 
endpoint of the study was disease-free survival. 
Secondary endpoints included overall survival and the 
effects of treatment on local-regional relapse. At a 
median follow up of 60 months, the overall 5-year 
disease-free survival was 94% and the overall survival 
was 98.2% for all patients enrolled. Patients treated with 
zoledronic acid had an improved disease-free survival 
(36% increase) and relapse-free survival (35% increase) 
than those patients not treated with the drug. Both 
findings were statistically significant. The authors 
concluded that zoledronic acid significantly improves 
clinical outcome beyond those achieved with endocrine 
therapy alone. The optimal dose, schedule and duration 
of therapy with zoledronic acid in this patient population 
still need to be established. 
Multi-Gene Assays to Predict Recurrence 
One of the most exciting advances in the area of 
cancer therapy has been the development of multi-gene 
assays which provide vital information on patient 
prognosis and potential response to systemic 
chemotherapy which would at least be complementary to 
the standard pathological and immunohistochemical 
techniques currently in use. An example would be the 
Oncotype DX® assay [72]. This test is particularly 
useful in patients with early stage estrogen receptor (+), 
lymph node (-) breast cancer. Two hundred and fifty 
candidate genes, potentially associated with breast cancer, 
were initially selected from the 25,000 genes in the 
human genome. Three independent studies and 447 
patients were studied to identify a final panel of genes 
that strongly correlated with recurrence-free survival. 
Sixteen genes were selected based upon these clinical 
trials along with five reference genes to normalise the 
expression of the cancer-related genes. The assay was 
tested prospectively to predict the recurrence of disease 
in tamoxifen-treated, node (-) breast cancer patients by 
the National Surgical Adjuvant Breast and Bowel Project 
(NSABP) [73]. Reverse-transcriptase-polymerase-chain-
reaction (RT-PRC) profiles were obtained in 675 tumour 
blocks from patients treated on the NSABP-14 trial. The 
results were used to calculate a recurrence score and to 
determine a risk group (low, intermediate, high) for each 
patient studied. Patients were considered low-risk if the 
recurrence score was < 18, based upon a total score of 
100, and high-risk with a recurrence score of ≥ 31. 
Intermediate-risk was defined as those patients with a 
recurrence score between 18 and 30. The Kaplan-Meier 
estimate for the patients in the low-risk group who were 
disease-free of distant recurrence at ten years was 93.2%. 
Patients in the high-risk group who were free of 
recurrence at 10 years was significantly less at 69.5% 
(p  <  0.001). Additional studies such as the prospective 
TAILORx Study are presently underway to validate 
these findings [74]. In this study, patients will be 
assigned to one of three treatment groups based upon 
their risk of distant recurrence as determined by the 
OncoType DX® assay. Patients with an Oncotype DX® 
recurrence score (ODRS) of < 11 (Group 1) will receive 
standard hormonal therapy alone. The drug choice will 
be at the discretion of the treating physician. Group 2, 
ODRS of 11-25 will be stratified according to tumour 
size, menopausal status, etc and assigned to either Arm I 
(experimental) – patients receiving hormonal therapy as 
in Group 1 – or Arm II (standard) – patients receiving 
standard combination chemotherapy followed by 
hormonal therapy as in Group 1. Group 3, ODRS > 25, 
will receive combination chemotherapy followed by 
hormonal therapy as in Group 1. The primary objectives 
of the study are to compare the disease-free survival of 
women with previously resected axillary lymph node (-) 
cancer with an ORDS of 11-25 treated with adjuvant 
chemotherapy and hormonal therapy versus adjuvant 
hormonal therapy alone. The study was also conducted to 
compare the distant recurrence-free interval and overall 
survival in patients with an ODRS of 11-25 treated with 
these regimens. Secondary endpoints include 
determining if adjuvant hormonal therapy alone is 
sufficient treatment for patients with ORDS < 11 and 
determining their disease-free survival, recurrence-free 
interval and overall survival. The results of this trial may 
dramatically change the way in which women with early 
stage ER(+), node (-) breast cancer are treated. 
Another microarray available for the evaluation of 
patients with early stage breast cancer is the 
MammaPrint® assay [75]. It is a 70-gene assay which 
focuses on proliferation, with additional genes associated 
with invasion, metastasis, stromal integrity and 
angiogenesis. Unlike the OncoType DX® assay, this test 
requires either fresh frozen tumour samples or tissues 
collected into an RNA preservative solution. It is 
currently offered as a prognostic test for women under 
the age of 61 with either estrogen receptor positive or 
negative, lymph node negative breast cancer. The test 
reports either high- or low-risk patients based upon the 
results of the assay. A validation study found the low-
risk group having a greater than 90 percent chance of 
being disease-free for a minimum of five years [76].  
An abstract reported at the 2007 San Antonio Breast 
Cancer Symposium [77] reported overall survival data at 
8 years for patients either treated or not treated with 
chemotherapy depending upon their MammaPrint® 
assay score. Patients receiving chemotherapy with a 
good profile (n=39) had an 8-year overall survival of 
95%. This compared with an overall survival of 94% in 
57 patients with a good profile that did not receive 
chemotherapy. Patients with a poor profile (n=142) had 
an overall survival of 73% at 8 years. This study 
validates the earlier findings proving the utility of the 
MammaPrint® in this patient population. 
The potential importance of multi-gene assays such 
as the Oncotype DX® assay and MammaPrint® assay 
adds a new dimension in the attempt to tailor 
chemotherapy to the individual patient and treat only 
those patients who would truly benefit. Ongoing studies 
will validate the usefulness of this type of testing. 
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Summary of Advances in Chemotherapy and Supportive 
Care 
The recent advances in the treatment of cancer – 
targeted therapy, more effective anti-emetics, the 
utilisation of growth factors, emphasis on bone health 
and the advent of genomic testing – have made it much 
easier to treat patients and achieve improved outcomes, 
making most malignancies chronic diseases. This trend 
will continue into the foreseeable future with over 250 
new compounds presently in clinical trial (see Table 6). 
Targeted therapy, improved supportive care drugs, and 
genomic testing all have the potential to improve the 
outcomes in patients with various malignancies. There is, 
however, significant added cost for these new drugs and 
technology which may limit their approval and utilisation 
in some parts of Asia. 
Challenges for Implementation of Advanced Cancer 
Care in Asia 
As with any treatment for cancer, a number of 
potential problems need to be addressed. They include, 
but are not limited to, the following: 
●  Access to adequate health care 
○  The role of alternative medicine 
●  Availability of newer agents 
○  Patent protection 
●  Expense of newer agents 
●  Complexity of prescribed regimen 
●  Toxicities of therapy and ability to treat them 
○  Hospitalisation 
○  Access to supportive care agents 
●  Knowledge synthesis and transfer  
●  Palliative and supportive care 
Chemotherapy Summary 
Chemotherapy has changed a great deal over the 
past 20 years. It has gone from an attempt to eradicate all 
dividing cells with the hope that normal cells would 
repair the damage more readily and with greater success 
than the malignant cell clones, to a better understanding 
of the molecular changes which malignant cells undergo. 
This improved understanding has helped in the 
development of targeted therapy that is more effective 
and less toxic. Improved palliative and supportive care 
have also added to improved response rates, overall 
survival and quality of life for patients with the diagnosis 
of cancer. Coupled with multi-gene assays which assess 
a patient’s risk for relapse, these help to better identify 
those patients who will benefit from the administration 
of these therapies. New drug development, with over 250 
compounds in active clinical trials, will also aid in the 
improved survival of patients with the diagnosis. The 
costs of these agents, as well as the combinations in 
which they are used, may well dictate the success of our 
fight against cancer in the very near future. 
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